<DOC>
	<DOCNO>NCT01345552</DOCNO>
	<brief_summary>The purpose study evaluate feasibility stereotactic body radiation ( SRS ) patient recurrent oligometastatic disease .</brief_summary>
	<brief_title>Radiosurgery Patients Recurrent Oligometastatic Disease</brief_title>
	<detailed_description>Patients limited disease recurrence , know oligometastatic oligorecurrent disease ( defined 5 few site metastatic disease ) benefit term overall survival disease progression reduce tumor burden improve local control via radiation oligometastatic site .</detailed_description>
	<criteria>3.1 Conditions Patient Eligibility 3.1.1 Pathologically ( histologically cytologically ) proven diagnosis solid malignancy 3.1.2 Eligible disease site include follow Breast Prostate GI ( include colorectal , anal , esophagus , pancreas , gastric exception patient colon cancer liveronly metastatic disease ) Head neck Skin ( melanoma squamous cell carcinoma ) Lung ( small cell nonsmall cell ) Sarcoma ( soft tissue bone ) Gynecologic ( endometrial , cervical , ovarian , vaginal , vulvar ) 3.1.3 Patients stage IV ( M1 ) recurrent combination T N oligometastatic disease define 5 few total sit metastatic disease 3.1.4 Can recurrent disease primary disease ( definition oligorecurrent disease ) primary cancer diagnose treat within last 3 year cutaneous skin cancer . 3.1.5 Prior systemic chemotherapy allowable 3.1.4 Zubrod Performance Status 01 3.1.5 Age ≥ 18 3.1.6 CBC/differential obtain within 4 week prior registration study , adequate bone marrow function define follow : 3.1.6.1 Absolute neutrophil count ( ANC ) ≥ 1,800 cells/mm3 ; 3.1.6.2 Platelets ≥ 100,000 cells/mm3 ; 3.1.6.3 Hemoglobin ≥ 8.0 g/dl ( Note : The use transfusion intervention achieve Hgb ≥ 8.0 g/dl acceptable . ) ; 3.1.7 Women childbearing potential male participant must practice adequate contraception 3.1.8 Patient must provide study specific informed consent prior study entry 3.2.1 Ineligible disease site include follow Lymphoma Leukemia Multiple myeloma Primary CNS Peritoneal carcinomatosis Colon cancer liveronly metastatic disease treatable surgical resection 3.2.2 Other Diffuse metastatic spread confine one organ system ineligible ; example include leptomeningeal spread CNS peritoneal carcinomatosis . Metastatic disease site must treatable stereotactic radiosurgery ( discretion treat physician ) . Patients oligometastatic site amenable SRS treatment , either size location , ineligible trial . 3.2.4 Severe , active comorbidity , define follow : 3.2.4.1 Unstable angina and/or congestive heart failure require hospitalization within last 6 month ; 3.2.4.2 Transmural myocardial infarction within last 6 month ; 3.2.4.3 Acute bacterial fungal infection require intravenous antibiotic time registration ; 3.2.4.4 Hepatic insufficiency result clinical jaundice and/or coagulation defect ; note , however , laboratory test liver function coagulation parameter require entry protocol . 3.2.5 Pregnancy woman childbearing potential men sexually active willing/able use medically acceptable form contraception ; exclusion necessary treatment involve study may significantly teratogenic . 3.2.6 Patients unable FDGPET scan , either insurance coverage , patient decision reason eligible study . 3.2.7 Oligometastatic disease site eligible base concern toxicity : trachea involvement ( direct invasion , tumor close abut trachea eligible ) heart ( direct invasion involvement , pericardial lymph node treat ) 3.2.8 Patients unable SRS insurance coverage ability pay SRS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Oligo mets</keyword>
	<keyword>Oligometastatic disease</keyword>
</DOC>